One-year outcomes after switching to faricimab in eyes with pre-treated neovascular age-related macular degeneration: a Swiss Retina Research Network report.

IF 4.4 Q1 OPHTHALMOLOGY
Gabriela Grimaldi, Aude Ambresin, Isabel B Pfister, Christin Schild, Christina Plasencia, Katja Hatz, Richard Stillenmunkes, Marion R Munk, Arianna Paris, Moreno Menghini, Dmitri Artemiev, Andreas Ebneter, Jennifer Cattaneo, Eva C de Oliveira Figueiredo, Chiara M Eandi, Jacqueline Fröhlich, Nicolas Feltgen, Tahm Spitznagel, Gábor Márk Somfai, Mariano Cozzi, Sandrine Zweifel, Andreas Weinberger, Justus G Garweg
{"title":"One-year outcomes after switching to faricimab in eyes with pre-treated neovascular age-related macular degeneration: a Swiss Retina Research Network report.","authors":"Gabriela Grimaldi, Aude Ambresin, Isabel B Pfister, Christin Schild, Christina Plasencia, Katja Hatz, Richard Stillenmunkes, Marion R Munk, Arianna Paris, Moreno Menghini, Dmitri Artemiev, Andreas Ebneter, Jennifer Cattaneo, Eva C de Oliveira Figueiredo, Chiara M Eandi, Jacqueline Fröhlich, Nicolas Feltgen, Tahm Spitznagel, Gábor Márk Somfai, Mariano Cozzi, Sandrine Zweifel, Andreas Weinberger, Justus G Garweg","doi":"10.1016/j.oret.2025.03.015","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pre-treated neovascular age-related macular degeneration (nAMD).</p><p><strong>Design: </strong>Retrospective, multicenter, longitudinal observational study conducted at 11 centers of the Swiss Retina Research Network.</p><p><strong>Subjects: </strong>We included 353 eyes of 325 patients who were switched to intravitreal faricimab after prior anti-vascular endothelial growth factor (anti-VEGF) therapy and followed for a minimum of 12 months between May 1, 2022 and October 30, 2024.</p><p><strong>Methods: </strong>Demographic characteristics, baseline functional and optical coherence tomography findings, treatment history, and outcomes at 12 months post-switch to faricimab were extracted from the patients' electronic case report forms.</p><p><strong>Main outcome measures: </strong>Change in best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) and pigment epithelial detachment, treatment intervals and safety signals.</p><p><strong>Results: </strong>Twelve months after switch, mean BCVA remained unchanged while mean CST decreased from 315.3 μm to 263.9 μm (p<0.01). Fast drying (absence of RF) after 1 faricimab injection was observed in 134 eyes (38%) and correlated positively with the treatment interval at 12 months (r(301)=0.24, p<0.01). After 12 months,169 (47.9%) eyes demonstrated absence of retinal fluid compared to 10.2% at switch. Mean treatment interval increased from 5.8 ± 2.5 weeks at switch to 8.3 ± 4.2 weeks at 12 months, whereas extended treatment intervals (≥12-week) were achieved in 20% of patients. Mild intraocular inflammation was reported in 1.7% of cases.</p><p><strong>Conclusions: </strong>Switching to faricimab in pre-treated nAMD led to sustained anatomical improvements and stabilization of BCVA, with a substantial reduction in RF compared to baseline. Our results suggest the potential benefits of this switch strategy based on real-world data.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2025.03.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pre-treated neovascular age-related macular degeneration (nAMD).

Design: Retrospective, multicenter, longitudinal observational study conducted at 11 centers of the Swiss Retina Research Network.

Subjects: We included 353 eyes of 325 patients who were switched to intravitreal faricimab after prior anti-vascular endothelial growth factor (anti-VEGF) therapy and followed for a minimum of 12 months between May 1, 2022 and October 30, 2024.

Methods: Demographic characteristics, baseline functional and optical coherence tomography findings, treatment history, and outcomes at 12 months post-switch to faricimab were extracted from the patients' electronic case report forms.

Main outcome measures: Change in best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) and pigment epithelial detachment, treatment intervals and safety signals.

Results: Twelve months after switch, mean BCVA remained unchanged while mean CST decreased from 315.3 μm to 263.9 μm (p<0.01). Fast drying (absence of RF) after 1 faricimab injection was observed in 134 eyes (38%) and correlated positively with the treatment interval at 12 months (r(301)=0.24, p<0.01). After 12 months,169 (47.9%) eyes demonstrated absence of retinal fluid compared to 10.2% at switch. Mean treatment interval increased from 5.8 ± 2.5 weeks at switch to 8.3 ± 4.2 weeks at 12 months, whereas extended treatment intervals (≥12-week) were achieved in 20% of patients. Mild intraocular inflammation was reported in 1.7% of cases.

Conclusions: Switching to faricimab in pre-treated nAMD led to sustained anatomical improvements and stabilization of BCVA, with a substantial reduction in RF compared to baseline. Our results suggest the potential benefits of this switch strategy based on real-world data.

一份瑞士视网膜研究网络报告:法利昔单抗治疗前新生血管性年龄相关性黄斑变性患者后一年的疗效
目的:报告在瑞士一个真实世界中预先接受治疗的新生血管性年龄相关性黄斑变性(nAMD)患者队列中改用法尼单抗的疗效和安全性:设计:在瑞士视网膜研究网络的 11 个中心进行的回顾性、多中心、纵向观察研究:我们纳入了325名患者的353只眼睛,这些患者在之前接受过抗血管内皮生长因子(anti-VEGF)治疗后转为使用玻璃体内法替单抗,并在2022年5月1日至2024年10月30日期间接受了至少12个月的随访:从患者的电子病例报告表中提取人口统计学特征、基线功能和光学相干断层扫描结果、治疗史以及转用法替单抗后12个月的结果:主要结果测量指标:最佳矫正视力(BCVA)、中央子野厚度(CST)、视网膜积液(RF)和色素上皮脱落、治疗间隔和安全信号的变化:结果:换药 12 个月后,平均 BCVA 保持不变,而平均 CST 则从 315.3 μm 降至 263.9 μm(p结论:在接受预处理的 nAMD 患者中改用法尼单抗治疗后,BCVA 的解剖结构得到持续改善并趋于稳定,RF 与基线相比大幅下降。我们的结果表明,基于真实世界的数据,这种转换策略具有潜在的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ophthalmology. Retina
Ophthalmology. Retina Medicine-Ophthalmology
CiteScore
7.80
自引率
6.70%
发文量
274
审稿时长
33 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信